



July 2024

Dear Healthcare Provider,

The purpose of this letter is to inform you that effective July 9, 2024, Indivior will discontinue sales and marketing activities related to PERSERIS[®] (risperidone) for extended-release injectable suspension. Indivior has taken this action due to expected adverse impacts from increased payor management of the treatment category in which PERSERIS[®] participates. It is not the result of any safety or efficacy issues related to the product.

Patient needs drive our decision making and we are committed to ensuring that we do not negatively impact patients who currently rely on PERSERIS[®] as part of their treatment. While we will no longer actively market PERSERIS[®], we will continue to supply PERSERIS[®]. We expect that product will be available for a minimum of a year to minimize disruption to patient treatment.

During the transition, our medical team is available to assist you and answer any medical inquires you might have. They can be reached at infoMIU@indivior.com or by calling 1-877-782-6966.

To report a pregnancy or side effects associated with taking PERSERIS[®] or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966.

Full prescribing information for PERSERIS[®] is available at: <https://www.perserishcp.com/prescribing-information.pdf>

Thank you for your continued partnership and commitment to provide the best care for your patients.

Sincerely,

Ann Wheeler, PharmD

Ann Wheeler, PharmD
Vice President, North America Medical Affairs
Indivior Inc.

